Please login to the form below

Not currently logged in
Email:
Password:

checkpoint inhibitor

This page shows the latest checkpoint inhibitor news and features for those working in and with pharma, biotech and healthcare.

New products help lift Roche outlook despite biosimilar onslaught

New products help lift Roche outlook despite biosimilar onslaught

$787m). Roche now expects to shortly unveil phase 3 results in liver cancer, which will help Tecentriq consolidate its position as the third biggest checkpoint inhibitor behind Merck &Co's Keytruda

Latest news

More from news
Approximately 2 fully matching, plus 147 partially matching documents found.

Latest Intelligence

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    cells to identify and fight cancer: the PD-1 and PD-L1 checkpoint inhibitor immunotherapies. ... 50%. The true figure for patients treated with checkpoint inhibitor monotherapy achieving durable and meaningful clinical responses is in fact nearer 20%.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Merck/MSD looks to have gained a dominant position in checkpoint inhibitor immuno-oncology (IO) with Keytruda – but there remains room for growth in the market via new IO agents. ... t the only oral JAK inhibitor developer with its eye on that

  • Is China ready for a pharmaceutical gold rush?

    The programmed cell death 1 (PD-1) immune checkpoint inhibitor works by restoring the immune system’s ability to fight cancer tumours. ... In light of recent clinical data, Keytruda is widely regarded as the better of the two checkpoint inhibitors in

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    There’s little doubt immunotherapy is leading the charge at the moment, headed by checkpoint inhibitors that target receptors that inhibit the patient’s own immune response, as well as ... Meanwhile, despite the mixed results for checkpoint inhibitor

  • Deal Watch January 2017 Deal Watch January 2017

    But it was not all inward traffic with the company announcing a global collaboration with Ovid to jointly develop and commercialise Takeda's selective CH24H inhibitor TAK-935 for the treatment ... 3, 050. Pieris Pharmaceuti-cals. Servier. Exclusive

More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics